<DOC>
	<DOCNO>NCT00307931</DOCNO>
	<brief_summary>An open-label multi-center single-cohort study assess safety efficacy certolizumab pegol treatment sign symptom active Crohn 's disease Greek patient previously respond infliximab longer sustain response become intolerant infliximab</brief_summary>
	<brief_title>Certolizumab Pegol Treatment Adult Greek Patients With Moderate Severe Crohn 's Disease Who Failed Infliximab</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>â€¢ Adult men woman Crohn 's disease previously responsive infliximab become nonresponsive intolerant Symptomatic obstructive intestinal stricture Bowel resection within 4 week Current total parenteral nutrition Short bowel syndrome Concomitant disease pathological condition could interfere Crohn 's disease harmful well patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>Greek patient</keyword>
</DOC>